Quantum Biopharma (QNTM) Liabilities and Shareholders Equity (2018 - 2026)

Quantum Biopharma has reported Liabilities and Shareholders Equity for 9 years, with the latest figure at $14.9 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity changed 0.35% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.5 million (down 16.19% YoY) and the FY2025 annual result came in at $11.2 million, down 34.8% from the prior year.
• Liabilities and Shareholders Equity grew to $14.9 million in Q1 2026 per QNTM's latest filing, from $11.2 million in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $38.4 million in Q4 2022 and troughed at $11.2 million in Q4 2025.
• A 5-year average of $17.8 million and a median of $15.3 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity slumped 54.51% in 2023, then increased 0.35% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $38.4 million in 2022, then plunged by 54.51% to $17.5 million in 2023, then declined by 2.03% to $17.1 million in 2024, then slumped by 34.8% to $11.2 million in 2025, then soared by 33.74% to $14.9 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $14.9 million, $11.2 million, and $14.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.